Xtant Medical reports 46.60 percent short-interest drop for Xtant Medical stock

Published on 10/18/2026 at 13:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Short interest fell 46.60 percent to 143,564 shares on September 30, 2026. Xtant Medical stock centers on its next report.

September short interest and results

Short interest fell 46.60 percent to 143,564 shares on September 30, 2026.
Second-quarter 2026 revenue was USD 23.03 million, down from USD 35.41 million.
MarketBeat estimates the next earnings date as November 10, 2026.

XTNT, US98420P3082, Illustration mit AI erstellt.

Xtant Medical Holdings (ISIN US98420P3082) saw short interest fall 46.60 percent to 143,564 shares on September 30, 2026, from 268,742 shares on September 15, according to Transcript Daily. The percentage change in short interest contrasts with the companys latest reported loss and lower revenue.

Short interest falls to 143,564 shares

The September 30 figure was 46.60 percent below the September 15 total. Transcript Daily also reported that short interest represented 0.10 percent of Xtant Medicals stock, while Loop Capital had set a USD 1.00 price target in a September 2, 2026 research report.

What changed across three events?

The companys recent chronology shows three quantified developments. On December 1, 2025, Xtant Medical completed divestitures with an aggregate purchase price of USD 21.40 million, according to MarketWatch. On April 13, 2026, it entered a distribution agreement for HEMOBLAST Bellows and paid a USD 5.00 million exclusivity fee. The September 30 short-interest figure came last.

The latest operating comparison is less favorable. Revenue in the second quarter of 2026 was USD 23.03 million, versus USD 35.41 million in the second quarter of 2025, while net loss was USD 9.41 million compared with net income of USD 3.55 million. The figures come from Xtant Medicals Form 10-Q carried by MarketWatch.

When is the next report?

MarketBeat estimates that Xtant Medical will report third-quarter 2026 results on November 10, 2026, before the market opens. Its consensus estimate is a loss of USD 0.03 per share on revenue of USD 25.48 million.

Losses keep the operating risk visible

The second-quarter filing also showed USD 7.31 million in cash used in operating activities during the quarter and total assets of USD 79.67 million as of June 30, 2026. For investors, the short-interest decline is measurable, but the next report must show whether revenue and cash generation are stabilizing.

On the NYSE American, Xtant Medical closed at USD 0.29 on October 16, 2026. The 52-week range was USD 0.27 to USD 0.95, and market capitalization was USD 40.2 million as of October 16, 2026.